Barclays PLC Grows Position in Arcus Biosciences, Inc. (NYSE:RCUS)

Barclays PLC boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 49.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 118,693 shares of the company’s stock after acquiring an additional 39,015 shares during the quarter. Barclays PLC owned about 0.13% of Arcus Biosciences worth $1,816,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. FMR LLC grew its stake in Arcus Biosciences by 6.9% in the 3rd quarter. FMR LLC now owns 4,467,557 shares of the company’s stock worth $68,309,000 after acquiring an additional 286,766 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of Arcus Biosciences by 32.9% in the third quarter. Point72 Asset Management L.P. now owns 2,437,073 shares of the company’s stock valued at $37,263,000 after purchasing an additional 603,222 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in shares of Arcus Biosciences by 146.9% in the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company’s stock valued at $15,684,000 after purchasing an additional 610,219 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Arcus Biosciences by 25.1% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock valued at $14,236,000 after acquiring an additional 186,750 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Arcus Biosciences by 11.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock worth $8,669,000 after acquiring an additional 59,536 shares during the period. 92.89% of the stock is owned by hedge funds and other institutional investors.

Arcus Biosciences Trading Down 3.5 %

Shares of Arcus Biosciences stock opened at $15.27 on Friday. The firm has a fifty day moving average price of $16.12 and a 200 day moving average price of $16.05. The stock has a market cap of $1.40 billion, a PE ratio of -4.85 and a beta of 0.88. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. Arcus Biosciences, Inc. has a 1 year low of $13.52 and a 1 year high of $20.31.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.06. The company had revenue of $48.00 million for the quarter, compared to the consensus estimate of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. Arcus Biosciences’s revenue for the quarter was up 50.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.94) earnings per share. Equities research analysts predict that Arcus Biosciences, Inc. will post -3.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on RCUS shares. HC Wainwright restated a “neutral” rating and set a $20.00 target price on shares of Arcus Biosciences in a report on Wednesday, November 6th. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Barclays increased their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Finally, Wells Fargo & Company started coverage on shares of Arcus Biosciences in a report on Tuesday, October 8th. They set an “overweight” rating and a $29.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $34.00.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.